Pharmacokinetic Evaluations of Tabalumab Following Subcutaneous Administration by Prefilled Syringe or Auto Injector in Patients With Systemic Lupus Erythematosus
Phase of Trial: Phase III
Latest Information Update: 09 May 2016
At a glance
- Drugs Tabalumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacokinetics; Registrational
- Sponsors Eli Lilly
- 08 Apr 2016 Status changed from completed to discontinued.
- 06 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.